Market Overview

UPDATE: Citigroup Initiates Coverage on Alexion Pharmaceuticals with Neutral Rating, $104 PT

Share:
Related ALXN
JP Morgan Moves Alexion Pharma To Overweight, Says Strensiq And Kanuma Are $1.7B Opportunity
Wall Street Mixed On Biogen Before Earnings
Amgen, Alexion Profits Beat (Investor's Business Daily)

In a report published Friday, Citigroup initiated coverage on Alexion Pharmaceuticals (NASDAQ: ALXN) with a Neutral rating and $104.00 price target.

Citigroup noted, “Alexion's Soliris has consistently exceeded expectations since its launch. The drug has become a late stage pipeline on its own and has driven Alexion to be a very successful beat and raise story. Accordingly, Alexion is now trading at a very high P/E multiple that reflects optimistic expectations for upward EPS revisions. If history is a guide, Alexion will need to post significant upside surprises to offset the natural P/E multiple contraction that is likely ahead. While we are optimistic about Soliris' growth, we are only in-line with consensus estimates in the next 2 years. Thus, in the absence of tremendous upside we are worried that the risk/reward profile of the stock is not attractive. We also anticipate that Soliris' label expansion into AHR, MG, and NMO will take 2 years longer than expected. Our doc checks also suggest that Soliris' high price could impede adoption in NMO and MG and limit the market opportunity.”

Alexion Pharmaceuticals closed on Thursday at $93.59.

Latest Ratings for ALXN

DateFirmActionFromTo
Jul 2015JP MorganAssumesOverweight
May 2015NomuraUpgradesNeutralBuy
May 2015CitigroupMaintainsNeutral

View More Analyst Ratings for ALXN
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color Initiation Analyst Ratings

 

Related Articles (ALXN)

Get Benzinga's Newsletters